{"protocolSection":{"identificationModule":{"nctId":"NCT03284762","orgStudyIdInfo":{"id":"18981"},"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation","officialTitle":"Xarelto® on Prevention of Stroke and Noncentral Nervous System systeMIc Embolism in Treatment Naïve Asian Patients With Non-valvular Atrial Fibrillation","acronym":"XaMINA"},"statusModule":{"statusVerifiedDate":"2020-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-09-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-08-09","type":"ACTUAL"},"completionDateStruct":{"date":"2019-11-20","type":"ACTUAL"},"studyFirstSubmitDate":"2017-09-14","studyFirstSubmitQcDate":"2017-09-14","studyFirstPostDateStruct":{"date":"2017-09-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-11-20","lastUpdatePostDateStruct":{"date":"2020-11-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"},"collaborators":[{"name":"Janssen Research & Development, LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of the study is to collect additional information of Xarelto treatment in routine clinical practice. Patients affected by atrial fibrillation and who will get Xarelto as a prophylactic treatment against stroke and systemic embolism (Stroke Prevention in Atrial Fibrillation) will be observed.","detailedDescription":"The study takes place in Korea and Taiwan. Approximately a total of 1200 patients will be included in the study within 12 months. The observation period for each patient is 1 year from enrollment into the study, or until withdrawal of consent or lost to follow-up. Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions."},"conditionsModule":{"conditions":["Atrial Fibrillation"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":1216,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment-naïve NVAF patients in Korea and Taiwan","description":"Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions. NVAF: Non-valvular atrial fibrillation","interventionNames":["Drug: Rivaroxaban (Xarelto, BAY59-7939)"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function","armGroupLabels":["Treatment-naïve NVAF patients in Korea and Taiwan"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Major bleeding events, collected as Serious Adverse Events (SAEs) or non-serious Adverse Events (AEs)","description":"Major bleeding events, collected as SAEs or non-serious AEs and defined as overt bleeding associated with:\n\n* A fall in hemoglobin of ≥2 g/dL, or\n* A transfusion of ≥2 units of packed red blood cells or whole blood, or\n* Occurrence at a critical site (intracranial, intra-spinal, intraocular, pericardial, intra articular, intra-muscular with compartment syndrome, retroperitoneal), or\n* Death.","timeFrame":"Up to one year"}],"secondaryOutcomes":[{"measure":"AEs","description":"All events which do not fall under characterization of major bleeding events as explained in section \"primary outcome variables\"","timeFrame":"Up to one year"},{"measure":"SAEs","description":"All events which do not fall under characterization of major bleeding events as explained in section \"primary outcome variables\"","timeFrame":"Up to one year"},{"measure":"All-cause mortality","description":"All events which do not fall under characterization of major bleeding events as explained in section \"primary outcome variables\"","timeFrame":"Up to one year"},{"measure":"Non-major bleeding events","description":"All events which do not fall under characterization of major bleeding events as explained in section \"primary outcome variables\"","timeFrame":"Up to one year"},{"measure":"Symptomatic thromboembolic events","description":"All events which do not fall under characterization of major bleeding events as explained in section \"primary outcome variables\"","timeFrame":"Up to one year"},{"measure":"Start of rivaroxaban therapy and, if applicable, stop of rivaroxaban therapy","description":"Start date and stop date will be collected to receive information on drug persistence","timeFrame":"Up to one year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female and male patients aged 19 years or older (Korea) and aged 20 years or older (Taiwan)\n* Diagnosis of NVAF\n* Patients for whom the decision to initiate treatment with rivaroxaban is made as per physician's routine treatment practice\n* Treatment naïve regarding stroke prevention for atrial fibrillation\n* Signed informed consent\n\nExclusion Criteria:\n\n* Contraindications for rivaroxaban according to the local market authorization/summary of product characteristics (SmPC)\n* Patients participating in an investigational program with interventions outside of routine clinical practice","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients from Taiwan and Korea visiting doctors in hospitals or medical practices for treatment of atrial fibrillation","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"Different facilities","city":"Multiple Locations","country":"Korea, Republic of"},{"facility":"Different facilities","city":"Multiple Locations","country":"Taiwan"}]},"referencesModule":{"references":[{"pmid":"35616848","type":"DERIVED","citation":"Liu PY, Choi EK, Kim TS, Kuo JY, Lee JM, On YK, Park SW, Park HW, Shin DG, Wang L, Yen HW, Lee MH; XaMINA Investigators. XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naive Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia. Adv Ther. 2022 Jul;39(7):3316-3333. doi: 10.1007/s12325-022-02102-8. Epub 2022 May 26."}],"seeAlsoLinks":[{"label":"Click here to find results for studies related to Bayer products","url":"http://clinicaltrials.bayer.com"}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED","description":"Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA \"Principles for responsible clinical trial data sharing\". This pertains to scope, time point and process of data access. As such, Bayer commits to sharing upon request from qualified researcher's patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"},{"id":"D000004617","term":"Embolism"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000016769","term":"Embolism and Thrombosis"},{"id":"D000014652","term":"Vascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M7474","name":"Embolism","asFound":"Embolism","relevance":"HIGH"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M16376","name":"Thrombosis","relevance":"LOW"},{"id":"M18818","name":"Embolism and Thrombosis","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}